血液系统恶性肿瘤患者颅内出血的结局与临床特征:系统文献综述
患者中位总生存期范围为20天至1.5个月,诊断血液系统恶性肿瘤后10天内发生颅内出血者中位总生存期仅5天。脑实质出血、多发出血灶、输血难治性低血小板计数、白细胞增多、就诊时低格拉斯哥昏迷评分及治疗早期发生颅内出血与更差结局相关。
要点
- 血液系统恶性肿瘤合并颅内出血患者生存期短,中位总生存期20天至1.5个月。
- 诊断后10天内发生颅内出血者中位总生存期仅5天。
- 脑实质出血、多发出血灶、输血难治性低血小板等提示预后不良。
核心结论
- 血液系统恶性肿瘤合并颅内出血患者生存期仍较差。
- 早期发现、识别不良预后因素及纠正血液学异常对预防和治疗颅内出血至关重要。
研究设计与样本
- 系统文献综述,遵循PRISMA指南,检索PubMed/MEDLINE、Web of Science、Ovid、SCOPUS和Embase数据库。
主要发现
- 所有患者中位总生存期范围为20天至1.5个月。
- 诊断血液系统恶性肿瘤后10天内发生颅内出血的患者中位总生存期为5天。
- 脑实质出血、多发出血灶、输血难治性低血小板计数、白细胞增多、就诊时低格拉斯哥昏迷评分及治疗早期发生颅内出血与更差结局相关。
临床怎么用
- 临床应早期检测颅内出血,识别不良预后因素,并纠正血液学异常以预防和治疗该人群颅内出血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many clinical and demographic factors can influence survival of patients with hematologic malignancies who have intracranial hemorrhages (ICHs). Understanding the influence of these factors on patient survival can guide treatment decisions and may inform prognostic discussions. We conducted a systematic literature review to determine survival of patients with intracranial hemorrhages and concomitant hematologic malignancy. METHODS: A systematic literature review was conducted and followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. PubMed/MEDLINE, Web of Science, Ovid, SCOPUS, and Embase databases were queried with the following terms: ("intracranial hemorrhages" OR "brain hemorrhage" OR "cerebral hemorrhage" OR "subdural hematoma" OR "epidural hematoma" OR "intraparenchymal hemorrhage") AND ("Hematologic Neoplasms" OR "Myeloproliferative Disorders" OR "Myelofibrosis" OR "Essential thrombocythemia" OR "Leukemia"). Abstracts and articles were screened according to inclusion and exclusion criteria that were determined a priori. RESULTS: Literature review yielded 975 abstracts from which a total of 68 full-text articles were reviewed. Twelve articles capturing 634 unique patients were included in the final qualitative analysis. Median overall survival for all patients ranged from 20 days to 1.5 months while median overall survival for the subset of patients having ICH within 10 days of diagnosis of hematologic malignancy was 5 days. Intraparenchymal hemorrhages, multiple foci of hemorrhage, transfusion-resistant low platelet counts, leukocytosis, low Glasgow Coma Scale scores at presentation, and ICH early in treatment course were associated with worse outcomes. CONCLUSIONS: Survival for patients with hematologic malignancies and concomitant ICHs remains poor. Early detection, recognition of poor prognostic factors, and correction of hematologic abnormalities essential to prevention and treatment of ICHs in this patient population.
引用
- Raghavan A, Wright CH, Wright JM, et al. Outcomes and Clinical Characteristics of Intracranial Hemorrhage in Patients with Hematologic Malignancies: A Systematic Literature Review. World Neurosurg. 2020. PMID: 32565374. doi:10.1016/j.wneu.2020.06.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。